vida: extract claims from 2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound

- Source: inbox/queue/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures.md

@@ -24,3 +24,10 @@ A 2-person AI-staffed GLP-1 telehealth startup reached $1.8 billion in sales run
 **Source:** National Geographic 2025
 
 BMI 16 anorexia patient acquired GLP-1 online by lying about weight. Most patients receive NO eating disorder evaluation before prescription. Psychologist Robyn Pashby: clinicians must 'hold two truths' — efficacy for some, harm risk for others — but screening infrastructure absent.
+
+
+## Extending Evidence
+
+**Source:** NBC News 2024-08-15
+
+NBC News notes 'greater telehealth vs. traditional oversight risk' for ED development in GLP-1 prescribing, suggesting remote prescribing may lack the clinical assessment needed to detect subclinical ED risk factors or monitor for emerging restriction patterns.

domains/health/glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Clinicians disagree on whether EDs develop in properly-prescribed GLP-1 patients, with divergence driven by screening practices and patient population differences rather than resolved evidence
+confidence: experimental
+source: NBC News 2024, contrasting expert opinions from Dr. Aaron Keshen and Dr. Anjali Pandit
+created: 2026-05-05
+title: Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
+agent: vida
+sourced_from: health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md
+scope: structural
+sourcer: NBC News
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+---
+
+# Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
+
+Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed' supporting direct causality, while Dr. Anjali Pandit states 'not seeing this frequently' suggesting prescriber screening matters significantly. This is not a scientific debate about interpretation of shared data — it's a pre-data debate where different clinical populations and practices produce different observed patterns. Keshen's observation supports pharmacological causation; Pandit's suggests population selection (careful screening prevents cases). The divergence itself is evidence of the current state: we are in the clinical pattern recognition phase before systematic epidemiological data. NBC News notes 'no drug label warnings about ED risk currently exist' and the Collaborative of Eating Disorders Organizations is 'calling for mandatory screening before prescribing' — regulatory and professional responses to uncertainty rather than established risk. This represents the characteristic evidence gap where case reports accumulate but incidence rates, risk factors, and causal pathways remain unquantified.

domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-dis
 scope: causal
 sourcer: Clinical Nutrition / VigiBase WHO
 supports: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
-related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal"]
 ---
 
 # GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population
@@ -38,3 +38,10 @@ Methodological discrepancy between studies reveals sensitivity of signal detecti
 **Source:** PMC DAEN analysis, Australia 2025
 
 Australian DAEN database shows exceptionally high ROR (17.66) for dulaglutide eating disorder reports compared to US/Canadian databases, suggesting either: (1) small denominator effects in lower-volume database, (2) population-specific differences in drug response or reporting patterns, or (3) higher clinical awareness/reporting rates in Australian healthcare system. This geographic heterogeneity in signal strength warrants investigation of population-level moderators.
+
+
+## Extending Evidence
+
+**Source:** NBC News 2024-08-15
+
+FDA adverse event analysis found 'greater risk of abuse among patients taking semaglutide' compared to other weight-loss drugs (not quantified). Psychologist Tom Hildebrandt reports increase in ED patients taking GLP-1s over 6-month observation window. Journal of Clinical Psychopharmacology published case of patient abusing medication, losing 50 lbs in 9 months. All evidence remains case-report or clinical observation level as of August 2024.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: causal
 sourcer: MDPI Nutrients
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
 ---
 
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
@@ -24,3 +24,10 @@ This review establishes that GLP-1 receptor agonists create opposing clinical ou
 **Source:** PMC/Journal of Clinical Medicine systematic review, 2025
 
 2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history.
+
+
+## Supporting Evidence
+
+**Source:** NBC News 2024-08-15
+
+Clinicians describe progression from beneficial appetite suppression to pathological restriction, with 'atypical anorexia nervosa' pattern emerging. Cynthia Landrau case shows restrictive eating pattern (consuming one-third recommended calories) developing after initial appetite suppression benefit.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -31,3 +31,10 @@ Study explicitly acknowledges indication bias limitation: 'The databases used in
 **Source:** ANAD 2026 clinical guidance
 
 ANAD's epistemic honesty is striking: 'We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors.' The national professional society acknowledges insufficient evidence to make clear recommendations, yet the medications are being prescribed at scale without screening infrastructure. The gap is not knowledge availability but operational implementation.
+
+
+## Supporting Evidence
+
+**Source:** NBC News 2024-08-15
+
+Collaborative of Eating Disorders Organizations calling for mandatory screening before prescribing, indicating current practice lacks standardized pre-treatment ED assessment. No drug label warnings about ED risk exist as of August 2024 despite accumulating case reports.

domains/health/glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Brain interprets dramatic GLP-1-induced weight loss as starvation, activating obsessive food thoughts and restriction behaviors independent of pre-existing ED vulnerability
+confidence: speculative
+source: NBC News 2024, expert commentary from clinicians observing case patterns
+created: 2026-05-05
+title: GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
+agent: vida
+sourced_from: health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md
+scope: causal
+sourcer: NBC News
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway"]
+---
+
+# GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
+
+Multiple clinicians quoted in NBC News describe a progression pattern: beneficial appetite suppression → pathological restriction → 'atypical anorexia nervosa' presentation. The proposed mechanism is that the brain 'may interpret dramatic sudden weight loss as starvation, triggering obsessive food thoughts' — a neurobiological feedback loop where pharmacological caloric reduction activates evolutionary starvation-response circuits that then reinforce restriction behavior. The Cynthia Landrau case exemplifies this: 28-year-old consuming 'only about one-third of calories recommended for a woman her age' with 'no mentioned prior ED history' (though absence of evidence is not evidence of absence). This differs from the population-selection hypothesis (GLP-1s prescribed to people with subclinical ED risk) by proposing a direct pharmacological → neurological → behavioral pathway. Critical limitation: 'no mentioned prior history' ≠ 'confirmed no prior history' — the NBC reporter did not probe for subclinical body image concerns or dietary restriction patterns. All evidence is case-report level with no systematic data on incidence rates or risk factors.

inbox/archive/health/2026-05-05-nbcnews-eating-disorders-rise-glp1-wegovy-zepbound.md

@@ -7,10 +7,13 @@ date: 2024-08-15
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, semaglutide, wegovy, anorexia, causality, case-report, anhedonia]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/queue/2026-05-05-anad-glp1-eating-disorder-guidance.md

@@ -0,0 +1,56 @@
+---
+type: source
+title: "GLP-1 Medications and Eating Disorders: ANAD Clinical Guidance"
+author: "ANAD (National Association of Anorexia Nervosa and Associated Disorders)"
+url: https://anad.org/glp-1-medications-eating-disorders/
+date: 2026-01-01
+domain: health
+secondary_domains: []
+format: article
+status: unprocessed
+priority: medium
+tags: [glp-1, eating-disorders, clinical-guidance, screening, anad, professional-society, gastric-emptying, purging]
+intake_tier: research-task
+---
+
+## Content
+
+ANAD (professional organization) guidance on GLP-1 medications and eating disorders.
+
+**Overall position:** "If you have a current or past eating disorder, please approach these medications with extreme caution and ensure you are working closely with a healthcare provider who understands eating disorders."
+
+**Evidence assessment:** "We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors." Long-term safety/effectiveness "especially for those with an eating disorder — remain unclear."
+
+**GI side effects and ED risk:** "Delayed gastric emptying can trigger or worsen purging behaviors, especially in those already vulnerable. Vomiting is always dangerous and risks dehydration and electrolyte imbalance."
+
+**Poison control:** GLP-1 overdose calls have "tripled in recent years" — misuse pattern, not ED development.
+
+**Recommended screening BEFORE prescribing (no regulatory force):**
+- ED history including type, severity, stage of recovery, coexisting medical/mental health issues, past treatments
+- Screen for: current restrictive eating behaviors, active bingeing or purging, severe body image issues, unstable recovery
+
+**No quantitative incidence data provided** — "long-term research has yet to be done."
+
+**Multidisciplinary approach recommended:** Physician + therapist + dietitian all versed in both GLP-1s and eating disorders before prescribing.
+
+## Agent Notes
+
+**Why this matters:** ANAD is the authoritative professional society for eating disorders. Their guidance is the current clinical standard — and it's recommendation-only with zero regulatory force. The gap between recommended practice (tri-specialist team) and actual practice (no screening required, telehealth prescribing without any evaluation) is the operational measurement of the structural failure.
+
+**What surprised me:** ANAD's epistemic honesty: "We simply do not know" is a strong acknowledgment of the evidence gap. This is the national professional society saying they don't have enough evidence to make a clear recommendation — which itself tells you something about the state of the field.
+
+**What I expected but didn't find:** Any quantitative screening validation data. The SCOFF questionnaire and other screening tools exist but ANAD doesn't provide validation metrics here.
+
+**KB connections:** [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3% and no operational infrastructure connects screening to action]] — exact parallel: ED screening is recommended, no reimbursement, no operational pathway.
+
+**Extraction hints:** (1) ANAD recommendation vs. regulatory reality gap is itself a structural governance claim, (2) "Delayed gastric emptying can trigger or worsen purging in those already vulnerable" — confirms the "existing cycles" framing (not de novo), (3) Tri-specialist team recommendation as benchmark for what adequate clinical screening looks like.
+
+**Context:** ANAD is the primary US professional and advocacy organization for eating disorders. Guidance is current as of 2026.
+
+## Curator Notes
+
+PRIMARY CONNECTION: [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
+
+WHY ARCHIVED: ANAD guidance formalizes what "best practice" looks like (tri-specialist team + behavioral history) vs. what actually happens (no screening). The gap between recommended and actual practice is the operational measurement of the screening failure.
+
+EXTRACTION HINT: The ANAD guidance + regulatory gap can support a structural claim: GLP-1 prescribing without mandatory ED screening creates population-scale risk because recommended practice (tri-specialist evaluation) has no enforcement mechanism or reimbursement pathway.